Koneksa has been awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to investigate the potential of digital biomarkers to evaluate and predict disease progression in people with Parkinson’s disease. Digital biomarkers have the potential to aid in diagnosing Parkinson’s and allowing patients…

Treatment with prasinezumab, a monoclonal antibody designed to break up toxic alpha-synuclein aggregates, failed to slow the progression of Parkinson’s disease in a Phase 2 clinical trial. “In this placebo-controlled trial, treatment with prasinezumab, a humanized monoclonal antibody targeting aggregated [alpha]-synuclein, had no meaningful effect on global clinical or…

Physical activity may be beneficial to brain health, including for people with neurodegenerative diseases such as Parkinson’s disease, by promoting increases in brain volume, a long-term follow-up study suggests. “Our study results indicate that even small behavioral changes, such as walking 15 minutes a day or taking the stairs…

Fluctuations in weight, either a loss or a gain, occurred significantly more often in people with Parkinson’s disease than in those without the progressive neurodegenerative disorder, a study has found. Weight loss in Parkinson’s patients was associated with a faster progression of motor and cognitive declines over a five-year…

Neo, my friendly brain conversationalist who engages with Mrs. Dr. C, inquiries about the Parkinson’s disease (PD) self-management toolkit. “It seems overwhelming.” Mrs. Dr. C suggests, “Would a review of the ideas, one by one, help?” Neo nods and gets comfortable. “I’ve read all the columns, but I do…

A miniature antibody-like molecule called a nanobody effectively broke up toxic alpha-synuclein aggregates that are characteristic of Parkinson’s disease, and prevented the spread of these aggregates in the brains of mice in a disease model. The novel construct was described in the journal Nature Communications, in the study, “…